Cyclopharm (CYC) Stock Price, News & Analysis

Company Overview

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 10,000 shs
• Average Volume: N/A
• Market Capitalization: A$219.50 million
• P/E Ratio: N/A
• Dividend Yield: 0.74%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: ASX:CYC
• CIK: N/A
• Web: www.cyclopharm.com.au
• Phone: 61 2 9541 0411
• Fax: N/A
• Employees: 87
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$9.32 million
• Net Margins: -40.69%
• Pretax Margin: N/A
• Return on Equity: -23.34%
• Return on Assets: -15.37%

Debt

• Debt-to-Equity Ratio: 11.72
• Current Ratio: 4.38
• Quick Ratio: 4.68

Sales & Book Value

• Annual Sales: A$24.06 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 8.40
• Book Value: A$0.50 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 111,140,000
• Free Float: N/A
• Market Cap: A$219.50 million
• Optionable: Not Optionable
• Beta: 0.70